Eruptive nevi under tocilizumab: first case report and data analysis

Abstract

we would like to draw attention to an unusual side effect of tocilizumab (TOC), a humanized monoclonal antibody directed against the interleukin 6 (IL-6) receptor, approved for the treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).

This article is protected by copyright. All rights reserved.

http://ift.tt/2qs1lGh